Cytovia, Cellectis add CAR-T targets to preexisting cell therapy pact; BridgeBio, Helsinn unveil first program in R&D tie-up
NK cell biotech Cytovia and gene editing firm Cellectis are expanding upon their previous team-up.
The two biotechs announced yesterday they have expanded their collaboration of gene-edited, iPSC-derived NK and CAR-NK cells to include new CAR targets and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics.
The amended deal, which was originally agreed to in February, now includes a $20 million equity stake in Cytovia stock by Cellectis, up from $15 million, alongside up to $805 million in milestones and royalty payments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
